{
    "clinical_study": {
        "@rank": "153154", 
        "arm_group": {
            "arm_group_label": "BAY1000394", 
            "arm_group_type": "Experimental", 
            "description": "Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days)."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety,\n      tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in\n      Japanese subjects with advanced malignancies."
        }, 
        "brief_title": "Japanese BAY1000394 Monotherapy Phase I Study", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese male or female subjects aged \u226520 years\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1\n\n          -  Life expectancy of at least 12 weeks\n\n          -  Subjects with advanced, histologically or cytologically confirmed solid tumors, not\n             amenable to any standard therapy, have no standard therapy available, or subjects\n             must have actively refused any treatment which would be regarded standard, and if in\n             the judgment of the investigator, experimental treatment is clinically and ethically\n             acceptable\n\n          -  At least 1 tumor lesion evaluable by computer tomography (CT) or scan or magnetic\n             resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors\n             (RECIST) version 1.1\n\n          -  Adequate bone marrow, liver, and renal functions\n\n        Exclusion Criteria:\n\n          -  Anticancer chemotherapy or immunotherapy within 4 weeks of study entry. Mitomycin C\n             or nitrosoureas should not be given within 6 weeks of study entry.\n\n          -  Radiotherapy to target lesions within 3 weeks prior to the first dose of study drug.\n\n          -  Use of biological response modifiers, such as granulocyte colony-stimulating factor\n             (G-CSF), within 3 weeks prior to the first dose of study drug.\n\n          -  Symptomatic metastatic brain or meningeal tumors.\n\n          -  Investigational drug treatment outside of this study during or within 4 weeks prior\n             to study entry.\n\n          -  Blood pressure <100/60 mmHg or pulse >100 BPM"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047890", 
            "org_study_id": "15200"
        }, 
        "intervention": [
            {
                "arm_group_label": "BAY1000394", 
                "description": "BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)", 
                "intervention_name": "BAY1000394 (2.5mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY1000394", 
                "description": "BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)", 
                "intervention_name": "BAY1000394 (5mg)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "CDK inhibitor", 
            "BAY1000394", 
            "Advanced malignancies", 
            "Japanese"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Kashiwa", 
                    "country": "Japan", 
                    "state": "Chiba", 
                    "zip": "277-8577"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of participants with abnormal lab parameters based on descriptive statistics", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Plasma concentration of BAY1000394", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)"
            }, 
            {
                "measure": "Plasma concentration of the metabolite M1 (BAY107-7746)", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 / Day 1: 0 (pre dose), 0.5, 1, 2, 4, 6, 8, 12 and 24 hours (Day 2, before morning dose). Cycle 1 / Day 10 : 0 (before morning dose), 0.5, 1, 2, 4, 6, 8 and 12 hours (before evening dose)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047890"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Tumor response", 
            "safety_issue": "No", 
            "time_frame": "Screening and on Day 21 of even numbered cycle"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}